Brokerages Set Glaukos Co. (NYSE:GKOS) PT at $130.45

Shares of Glaukos Co. (NYSE:GKOS) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $134.55.

Several equities analysts recently issued reports on the company. Piper Sandler set a $140.00 price objective on Glaukos in a research report on Thursday, October 17th. Needham & Company LLC increased their price target on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Wells Fargo & Company increased their price target on Glaukos from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday. Morgan Stanley increased their price target on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Finally, BTIG Research increased their price target on Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a report on Wednesday, August 28th.

Glaukos Stock Performance

Shares of GKOS opened at $139.33 on Tuesday. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average price is $129.72 and its 200-day moving average price is $120.48. Glaukos has a 52 week low of $59.22 and a 52 week high of $143.24. The stock has a market cap of $7.66 billion, a P/E ratio of -46.14 and a beta of 1.02.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. The firm had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative return on equity of 20.28% and a negative net margin of 42.43%. The business’s revenue for the quarter was up 23.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.50) EPS. Equities research analysts anticipate that Glaukos will post -2.16 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In related news, Director Marc Stapley sold 6,250 shares of Glaukos stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $125.93, for a total value of $787,062.50. Following the completion of the transaction, the director now owns 34,076 shares in the company, valued at approximately $4,291,190.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at $4,225,345.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Marc Stapley sold 6,250 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $125.93, for a total value of $787,062.50. Following the transaction, the director now owns 34,076 shares of the company’s stock, valued at $4,291,190.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,525 shares of company stock valued at $2,142,029. 6.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GKOS. Point72 Asset Management L.P. bought a new position in Glaukos in the second quarter worth approximately $67,460,000. Primecap Management Co. CA raised its stake in Glaukos by 43.9% in the second quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock worth $144,483,000 after buying an additional 372,180 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Glaukos by 148.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock worth $48,805,000 after buying an additional 246,322 shares in the last quarter. Iron Triangle Partners LP raised its stake in Glaukos by 75.6% in the first quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock worth $40,500,000 after buying an additional 184,919 shares in the last quarter. Finally, Driehaus Capital Management LLC raised its stake in Glaukos by 24.0% in the second quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier’s stock worth $95,112,000 after buying an additional 155,653 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.